Compare ARK Genomic Revolution ETF (ARKG) vs Kroger Co (KR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kroger Co — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Kroger Co trades at $60.45 (market cap $37.09B). The key difference: Kroger Co pays a 2.38% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Kroger Co nearer its low. Which is the better fit depends on your goals.
| ARKG | KR | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $75.60 |
52-Week Low | $23.09 | $55.53 |
Market Cap | — | $37.09B |
Enterprise Value | — | $57.18B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Kroger (KR) trades at $60.54, up 1.14% today, near the analyst consensus price target of $68.63. The stock shows bullish technical signals despite a mixed earnings history, with recent beats in Q3 and Q4 2025 but a miss in Q1 2026. Fundamentals reveal a low P/S ratio of 0.26 and steady dividends, while the recent $1.65 billion acquisition of Giant Eagle aims to expand Midwest presence amid intense grocery competition.
KR offers value with solid cash flow and growth initiatives, but risks include margin pressure from industry competition and integration challenges from acquisitions. Analyst sentiment is positive with 48% buy ratings, supporting a cautious bullish outlook for patient investors focused on long-term retail consolidation benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
